HUE034005T2 - Therapies for improving lung function - Google Patents

Therapies for improving lung function Download PDF

Info

Publication number
HUE034005T2
HUE034005T2 HUE11769881A HUE11769881A HUE034005T2 HU E034005 T2 HUE034005 T2 HU E034005T2 HU E11769881 A HUE11769881 A HU E11769881A HU E11769881 A HUE11769881 A HU E11769881A HU E034005 T2 HUE034005 T2 HU E034005T2
Authority
HU
Hungary
Prior art keywords
gly
ser
val
thr
seq
Prior art date
Application number
HUE11769881A
Other languages
English (en)
Hungarian (hu)
Inventor
Raffaella Faggioni
Richard May
Chris Kell
Nestor Molfino
Lorin Roskos
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HUE034005T2 publication Critical patent/HUE034005T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/08—Measuring devices for evaluating the respiratory organs
    • A61B5/087—Measuring breath flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
HUE11769881A 2010-10-15 2011-10-14 Therapies for improving lung function HUE034005T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39367710P 2010-10-15 2010-10-15
US201161508723P 2011-07-18 2011-07-18

Publications (1)

Publication Number Publication Date
HUE034005T2 true HUE034005T2 (en) 2018-01-29

Family

ID=44800047

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11769881A HUE034005T2 (en) 2010-10-15 2011-10-14 Therapies for improving lung function

Country Status (15)

Country Link
US (1) US20130281876A1 (enExample)
EP (1) EP2627673B1 (enExample)
JP (1) JP2013544235A (enExample)
CN (1) CN103328506A (enExample)
AU (1) AU2011315499A1 (enExample)
BR (1) BR112013009055A2 (enExample)
CA (1) CA2814431A1 (enExample)
DK (1) DK2627673T3 (enExample)
ES (1) ES2645368T3 (enExample)
HU (1) HUE034005T2 (enExample)
MX (1) MX2013004212A (enExample)
NO (1) NO2627673T3 (enExample)
PL (1) PL2627673T3 (enExample)
RU (1) RU2013122123A (enExample)
WO (1) WO2012049278A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
WO2015112970A1 (en) * 2014-01-27 2015-07-30 Medimmune, Llc Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EP3129497B1 (en) 2014-04-11 2021-09-08 Novartis AG Methods of selectively treating asthma using il-13 antagonists
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
AU2016205188A1 (en) 2015-01-09 2017-06-22 Medimmune, Llc Assay to detect human DPP-4
CN104605857A (zh) * 2015-02-12 2015-05-13 上海朔茂网络科技有限公司 一种肺功能测量方法
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
JP2020509025A (ja) * 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
MA55204A (fr) 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
WO2022026922A2 (en) * 2020-07-31 2022-02-03 Genentech, Inc. Methods for treating exacerbations of inflammatory respiratory diseases
CN112341543B (zh) * 2021-01-11 2021-04-23 广东赛尔生物科技有限公司 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
JP2025501239A (ja) 2021-12-30 2025-01-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4/il-13アンタゴニストを投与することによってアトピーマーチを減弱する方法
WO2026151705A1 (en) * 2025-01-07 2026-07-16 Apogee Therapeutics, Inc. Dosage and administration of interleukin-13 antibody to treat asthma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2140660A1 (en) * 1993-06-13 1994-12-22 Uwe R. Juergens Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
WO2006055638A2 (en) * 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
EP2627673A1 (en) 2013-08-21
BR112013009055A2 (pt) 2016-07-19
EP2627673B1 (en) 2017-07-26
DK2627673T3 (da) 2017-11-06
NO2627673T3 (enExample) 2017-12-23
US20130281876A1 (en) 2013-10-24
CN103328506A (zh) 2013-09-25
MX2013004212A (es) 2013-09-02
RU2013122123A (ru) 2014-11-20
JP2013544235A (ja) 2013-12-12
PL2627673T3 (pl) 2018-01-31
WO2012049278A1 (en) 2012-04-19
ES2645368T3 (es) 2017-12-05
CA2814431A1 (en) 2012-04-19
AU2011315499A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
EP2627673B1 (en) Therapies for improving pulmonary function
US20250032608A1 (en) Treatment of asthma with anti-tsl p antibody
JP2013544235A5 (enExample)
CN107073114B (zh) 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
KR20260048354A (ko) Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
KR20240049348A (ko) 항-인터루킨-33 항체를 사용한 만성 폐쇄성 폐질환의 치료
KR20250140101A (ko) 항-tslp 항체를 이용한 만성 비부비동염의 치료
JP2025527762A (ja) 抗インターロイキン-33抗体を用いた喘息の治療
HK1188603B (en) Therapies for improving pulmonary function
HK1188603A (en) Therapies for improving pulmonary function
TW202544036A (zh) 用抗tslp抗體治療慢性阻塞性肺病
KR20260013478A (ko) 항-tslp 항체를 사용한 코르티코스테로이드 의존성 천식의 치료
WO2025120567A1 (en) Method of treatment of asthma
AU2024370739A1 (en) Treatment
HK40129804A (zh) 用抗白介素-33抗体治疗慢性阻塞性肺病
HK40114199A (en) Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody
Gauvreau et al. Inhaled Antisense for Treatment of Respiratory Disease
HK1240824B (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
HK1240824A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma